Clinical trial registration promotes patient protection and benefit, advances the trust of everyone, and is required

Chest

Volumn 131, Issue 3, 2007, Pages 639-641

  Irwin, Richard S ^a,b  

^a CHEST ^*

^b CHEST   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; CLINICAL RESEARCH; CLINICAL TRIAL; EDITORIAL; HUMAN; MEDICAL LITERATURE; PATIENT CARE; PRIORITY JOURNAL; PROTECTION; PUBLICATION; QUALITY ADJUSTED LIFE YEAR; REGISTER; REGISTRATION; SCIENTIFIC MISCONDUCT; STANDARD; TRUST;

EID: 33947359471     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-0088     Document Type: Editorial

References (18)

1. DeAngelis CD, Drazen JM, Frizelle FA, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA 2004; 292:1363-1364
2. DeAngelis CD, Drazen JM, Frizelle FA, et al. Is this clinical trial fully registered? - a statement from the International Committee of Medical Journal Editors. N Engl J Med 2005; 352:2436-2438
3. Barron JP. Introducing "Medical Writing Tips of the Month:" a new section in CHEST. Chest 2006; 129:506-507
4. Welch SJ. Preparing manuscripts for online submission: basic information and avoidance of common pitfall. Chest 2006; 129:822-825
5. Barron JP. The uniform requirements for manuscripts submitted to biomedical journals recommended by the International Committee of Medical Journal Editors. Chest 2006; 129:1098-1099
6. Zarin DA, Kesselman A. Registering a clinical trial in ClinicalTrials.gov. Chest 2007; 131:909-912
7. Sim I, Chan A-W, Gulmezoglu AM, et al. Clinical trial registration: transparency is the watchword. Lancet 2006; 367:1631-1633
8. Graham DJ. COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA 2006; 296:1653-1656
9. Steinman MA, Bero LA, Chren M-M, et al. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med 2006; 145:284-293
10. Armstrong D. Financial ties to industry cloud major depression study. The Wall Street Journal Online. July 11, 2006. Available at: wsj.com. Accessed July 13, 2006
11. Nylenna M, Simonsen S. Scientific misconduct: a new approach to prevention. Lancet 2006; 367:1882-1884
12. Miller FG, Brody H. Professional integrity industry-sponsored clinical trials. Acad Med 2005; 80:899-904
13. Institute of Medicine urges reforms at FDA [editorial]. Lancet 2006; 368:1211
14. Yaphe J, Edman R, Knishkowy B, et al. The association between funding by commercial interests and study outcomes in randomized controlled drug trials. Fam Pract 2001; 18: 565-568
15. Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326:1167-1170
16. Fries JF, Krishnan E. Equipoise, design bias, and randomized controlled trials: the elusive ethics of new drug development. Arthritis Res Ther 2004; 6:R250-R255
17. Bhandari M, Busse JW, Jackowski D, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. Can Med Assoc J 2004; 170:477-480
18. Ridker PM, Torres J. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. JAMA 2006; 295:2270-2274